498548-15-5

Upstream product

• 498548-14-4 2-(2,2-diphenylbenzo[1,3]dioxol-5-yl)-3,5,7-tribenzyloxy-4H-chromen-4-one 
• 117-39-5 quercetol 
• 100-44-7 benzyl chloride 
• 357194-03-7 2-(2,2-diphenylbenzo[1,3]dioxol-5-yl)-3,5,7-trihydroxychromen-4-one 

Downstream Products

• 1313191-84-2 2-(4-(2,3,4,6-tetra-O-acetyl)-β-D-glucopyranosyloxy-3-benzyloxyphenyl)-3,5,7-tribenzyloxy-4H-chromen-4-one 
• 1313191-85-3 2-(4-O-β-D-glucopyranosyloxy-3-benzyloxyphenyl)-3,5,7-tribenzyloxy-4H-chromen-4-one 
• 20229-56-5 spiraeoside 
• 1313191-83-1 C₄₃H₄₀O₁₆ 
• 1610737-61-5 3,7-bis(benzyloxy)-2-(4-((4-fluorobenzyl)oxy)-3-hydroxyphenyl)-5-hydroxy-4H-chromen-4-one 
• 1610737-79-5 2-(4-((4-fluorobenzyl)oxy)-3-hydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one 
• 498548-16-6 3,7-bis(benzyloxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one 
• 3306-17-0 3,7-bis-benzyloxy-2-(3,4-dimethoxy-phenyl)-5-hydroxy-chromen-4-one 
• 3306-18-1 3,7-bis-benzyloxy-2-(3,4-dimethoxy-phenyl)-5-methoxy-chromen-4-one 
• 603-61-2 tamarixetin 

Relevant academic research and scientific papers

QUERCETIN DERIVATIVE, PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME, AND METHOD FOR SYNTHESIZING THE SAME

The present invention relates to a novel quercetin derivative in which a 4′-hydroxy group of quercetin is substituted and which has excellent stability, to a pharmaceutical composition for preventing or treating cancer comprising the same, and to a synthe

Glucuronidation of Methylated Quercetin Derivatives: Chemical and Biochemical Approaches

Botanical supplements derived from grapes are functional in animal model systems for the amelioration of neurological conditions, including cognitive impairment. Rats fed with grape extracts accumulate 3′-O-methyl-quercetin-3-O-β-d-glucuronide (3) in their brains, suggesting 3 as a potential therapeutic agent. To develop methods for the synthesis of 3 and the related 4′-O-methyl-quercetin-7-O-β-d-glucuronide (4), 3-O-methyl-quercetin-3′-O-β-d-glucuronide (5), and 4′-O-methyl-quercetin-3′-O-β-d-glucuronide (6), which are not found in the brain, we have evaluated both enzymatic semisynthesis and full chemical synthetic approaches. Biocatalysis by mammalian UDP-glucuronosyltransferases generated multiple glucuronidated products from 4′-O-methylquercetin, and is not cost-effective. Chemical synthetic methods, on the other hand, provided good results; 3, 5, and 6 were obtained in six steps at 12, 18, and 30% overall yield, respectively, while 4 was synthesized in five steps at 34% overall yield. A mechanistic study on the unexpected regioselectivity observed in the quercetin glucuronide synthetic steps is also presented.

Regiospecific synthesis of three quercetin O-β-glucosides of N-acetylglucosamine

The regiospecific synthesis of three quercetin O-β-glucosides of N-acetylglucosamine has been achieved in good yield. Selective di- and tri-O-benzylation of quercetin followed by O-glycosylation with 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-d-glucopyranosyl chloride under phase-transfer catalysis conditions yielded, after deacetylation and debenzylation, 3-, 3′- and 4′-glycosylated quercetin.

Quercetin derivative and its preparation method and application

The invention discloses a quercetin derivative and a preparation method and application thereof. The preparation method comprises the following steps: firstly using dichlorodiphenylmethane to protect quercetin o-diphenol hydroxyl, combining a benzyl protection group to obtain the selectively protected quercetin derivative, and then independently reacting with dimethyl sulfate, diethyl sulfate, allyl bromide, paratoluensulfonyl chloride and acetic anhydride respectively to generate corresponding quercetin derivatives. All of the prepared derivative compounds have NRK-49F proliferation activity inhibition superior to that of quercetin. The quercetin derivatives 20a-1, 14a-1 and 23d-1 compositely replaced by methyl and p-tosyl have higher inhibition NRK-49F proliferation activity, and the inhibition ratio respectively reaches 86.33%, 78.04% and 75.91%. Thus, the currently obtained quercetin derivative compounds have obvious inhibition effect on kidney fibroblast NRK-49F proliferation.

Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75

HIV integrase (IN) is an essential enzyme for the viral replication. Currently, three IN inhibitors have been approved for treating HIV-1 infection. All three drugs selectively inhibit the strand transfer reaction by chelating a divalent metal ion in the

Regiospecific synthesis of quercetin O-β-d-glucosylated and O-β-d-glucuronidated isomers

Quercetin, the polyphenolic compound, which has the highest daily intake, is well known for its protective effects against aging diseases and has received a lot of attention for this reason. Both quercetin 3-O-β-d-glucuronide and quercetin 3′-O-β-d-glucuronide are human metabolites, which, together with their regioisomers, are required for biological as well as physical chemistry studies. We present here a novel synthetic route based on the sequential and selective protections of the hydroxyl functions of quercetin allowing selective glycosylation, followed by TEMPO-mediated oxidation to the glucuronide. This methodology enabled us to synthesize the five O-β-d-glucosides and four O-β-d-glucuronides of quercetin, including the major human metabolite, quercetin 3-O-β-d-glucuronide.

Hemisynthesis of all the O-monomethylated analogues of quercetin including the major metabolites, through selective protection of phenolic functions

A new methodology for the hemisynthesis of all the five O-monomethylated analogues of quercetin (3′-O-methylquercetin (isorhamnetin), 4′-O-methylquercetin (tamarixetin), 3-O-methylquercetin, 5-O-methylquercetin (azaleatin) and 7-O-methylquercetin (rhamnetin)) through sequential protection of the different phenolic functions of quercetin is reported.